Brainstorm recruits Novartis vet Araya as chief commercial officer; Roche out-licenses IPF drug to Shanghai's Ark
→ BrainStorm Cell Therapeutics $BCLI has appointed Novartis vet Arturo Araya as chief commercial officer. Araya had been global head of commercial of Novartis’ Cell and Gene Therapies Unit and has been on the board at Brainstorm since February of last year.
→ Roche struck a deal to out-license an IPF drug to Shanghai-based Ark Biosciences, helmed by CEO Jim Wu. The biotech got the global rights to the drug, which has been through the first round of human studies. The statement did not include any details on the financing.
→ Penny stock biotech Eyegate $EYEG says that its Phase III study of EGP-437 for uveitis flopped, leaving them looking at strategic alternatives as they look about for a fresh strategy. The biotech noted: “Although EGP-437 showed clinical efficacy, defined as a reduction in anterior chamber cell score throughout the study, it did not demonstrate non-inferiority to the prednisolone acetate ophthalmic solution control group. This was measured as the proportion of subjects with an anterior cell count of zero (a sign of diminished inflammation) at Day 14. EyeGate will continue to review the data and will be assessing its strategic options for EGP-437 going forward.”
→ Advaxis $ADXS has granted OS Therapies a license to test ADXS31-164, also known as ADXS-HER2, as a treatment for osteosarcoma. Advaxis gets an unspecified upfront payment and milestones for the deal.
→ Azeria, a spin out created by Sixth Element Capital and Cancer Research UK’s commercial partnerships team, has raised £4 million in Series A fundraising from the £70 million CRT Pioneer Fund.